$EBS Q3 '26 Earnings Results & Recap
• Reported GAAP EPS of -$0.36 down -131.30% YoY
• Reported revenue of $110M down -52.40% YoY
• Emergent BioSolutions revised its full-year 2026 forecast to total revenues of $600M, net loss of -$255M, adjusted EBITDA of $110M, and adjusted gross margin of 45%-47%.